1Wiseman, LR & Brogden, RN (1998) Propionyl-l-carnitine. Drugs Aging 12, 243–248.
2Binienda, Z & Virmani, A (2003) The mitochondriotropic effects of l-carnitine and its esters in the central nervous system. Curr Med Chem 3, 275–282.
3Siliprandi, N, Di Lisa, F & Menabò, R (1991) Propionyl-l-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5, 11–15.
4Alberti, KG, Zimmet, P, Shaw, J, et al. (2005) The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062.
5Avogaro, A & de Kreutzenberg, SV (2005) Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta 360, 9–26.
6Meigs, JB, Larson, MG, Fox, CS, et al. (2007) Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 30, 2529–2535.
7Furukawa, S, Fujita, T, Shimabukuro, M, et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114, 1752–1761.
8Kim, JA, Montagnani, M, Koh, KK, et al. (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888–1904.
9Bueno, R, Alvarez de Sotomayor, M, Perez-Guerrero, C, et al. (2005) l-Carnitine and propionyl-l-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci 77, 2082–2097.
10Alvarez de Sotomayor, M, Bueno, R, Pérez-Guerrero, C, et al. (2007) Effect of l-carnitine and propionyl-l-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res 44, 354–364.
11de Sotomayor, MA, Mingorance, C, Rodriguez-Rodriguez, R, et al. (2007) l-Carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms. Free Radic Res 41, 884–891.
12Santo, SS, Sergio, N, Luigi, DP, et al. (2006) Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Res Clin Pract 72, 231–237.
13Lango, R, Smoleński, RT, Rogowski, J, et al. (2005) Propionyl-l-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther 19, 267–275.
14Matthews, DR, Hosker, JP, Rudenski, AS, et al. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419.
15Zucker, LM & Antoniades, HN (1972) Insulin and obesity in the Zucker genetically obese rat ‘fatty’. Endocrinology 90, 1320–1330.
16Arvola, P, Wu, X, Kahonen, M, et al. (1999) Exercise enhances vasorelaxation in experimental obesity associated hypertension. Cardiovasc Res 43, 992–1002.
17He, Y & MacLeod, KM (2008) Modulation of noradrenaline-induced vasoconstriction in isolated perfused mesenteric arterial beds from obese Zucker rats in the presence and absence of insulin. Can J Physiol Pharmacol 80, 171–179.
18Subramanian, R & MacLeod, KM (2003) Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 477, 143–152.
19Galisteo, M, Sanchez, M, Vera, R, et al. (2005) A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-α in obese Zucker rats. J Nutr 135, 2399–2404.
20Frisbee, JC & Delp, MD (2006) Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 42, 145–161.
21Goldstein, BJ, Scalia, RG & Ma, XL (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6, 27–35.
22Gómez-Amores, L, Mate, A, Revilla, E, et al. (2006) Antioxidant activity of propionyl-l-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 78, 1945–1952.
23Calo, LA, Pagnin, E, Davis, PA, et al. (2006) Antioxidant effect of l-carnitine and its short chain esters. Relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 107, 54–60.
24Loffredo, L, Pignatelli, P & Cangemi, R (2006) Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc Surg 44, 525–530.
25Hiatt, WM, Regensteiner, JG, Creager, MA, et al. (2001) Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110, 616–622.
26Ferrari, R, Merli, E, Cicchitelli, G, et al. (2004) Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular disease: a review. Ann NY Acad Sci 1033, 79–91.
27Broderick, TL, Driedzic, W & Paulson, DJ (2000) Propionyl-l-carnitine effects on postischemic recovery of heart function and substrate oxidation in the diabetic rat. Mol Cell Biochem 206, 151–157.
28Power, RA, Hulver, MW, Zhang, JY, et al. (2007) Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 50, 824–832.
29Durham, HA & Truett, GE (2006) Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 290, R652–R658.